Mail

AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

0.541

-0.034 (-5.98%)

At close: 4:00PM EST

Stock chart is not supported by your current browser

Previous Close	0.575
Open	0.560
Bid	0.000 x 800
Ask	0.000 x 900
Day's Range	0.530 - 0.587
52 Week Range	0.350 - 4.950
Volume	521,046
Avg. Volume	1,662,401

Market Cap	57.734M
Beta (3Y Monthly)	0.91
PE Ratio (TTM)	N/A
EPS (TTM)	-0.125
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	14.00

Trade prices are not sourced from all markets

All

News

Press Releases

ACCESSWIRE13 days ago
3 Health Care Stocks Rallying After US Midterms
/ Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.
PR Newswire13 days ago
Ampio Updates Regulatory and Clinical Status for Ampion™
ENGLEWOOD, Colo., Nov. 7, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK). Ampio designed what it thought would be a final pivotal clinical trial of Ampion (AP-003-C), predominately under guidance from FDA CBER's Office of Blood Research and Review (OBRR).
GlobeNewswire21 days ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
NEW YORK, Oct. 30, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE)..
GlobeNewswire26 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ACCESSWIRE27 days ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
GlobeNewswire27 days ago
CLASS ACTION UPDATE for AMPE, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Oct. 24, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
GlobeNewswire28 days ago
Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.
Law Offices of Howard G. Smith reminds investors of the October 24, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) securities between December 14, 2017 and August 7, 2018, inclusive (the “Class Period”). Ampio investors have until October 24, 2018 to file a lead plaintiff motion.
GlobeNewswire28 days ago
SHAREHOLDER ALERT: AMPE LCI PZZA SKX PM USAT COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Oct. 23, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
GlobeNewswire28 days ago
WEDNESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
GlobeNewswire28 days ago
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ampio Pharmaceuticals, Inc. (AMPE) and Lead Plaintiff Deadline – October 24, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Ampio securities between December 14, 2017 through August 7, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ampe. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
GlobeNewswire29 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, OPK, QRTEA and HTHT
NEW YORK, Oct. 22, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
ACCESSWIRE29 days ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) of the October 24, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Ampio stock or options between December 14, 2017 and August 7, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMPE. You can also contact us by calling Richard Gonnello toll free at877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
ACCESSWIRE29 days ago
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 22, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
GlobeNewswire29 days ago
CLASS ACTION UPDATE for AMPE, ALNY and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Oct. 22, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
ACCESSWIRElast month
2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
GlobeNewswirelast month
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pinduoduo, CV Sciences, and Ampio and Encourages Investors to Contact the Firm
NEW YORK, Oct. 21, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Pinduoduo Inc., CV.
Business Wirelast month
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. to Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (AMPE) of the October 24, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Ampio stock or options between December 14, 2017 and August 7, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMPE. The case, Jun Shi v. Ampio Pharmaceuticals, Inc. et al., No. 18-cv-07476 was filed on August 25, 2018 and has been assigned to Judge S. James Otero.
GlobeNewswirelast month
SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Oct. 21, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
ACCESSWIRElast month
October 24 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 20, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
GlobeNewswirelast month
AMPE OCT. 24 ALERT: Rosen Law Firm Reminds Ampio Pharmaceuticals, Inc. Investors of Important Deadline in First Filed Case Commenced by Firm – AMPE
NEW YORK, Oct. 20, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) from December 14,.
GlobeNewswirelast month
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ampio Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AMPE
Pomerantz LLP announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and index under 18-cv-02252, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.
GlobeNewswirelast month
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.
National class action law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 24, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) securities between December 14, 2017, and August 7, 2018, inclusive (the “Class Period”). Ampio investors have until October 24, 2018 to file a lead plaintiff motion. On August 7, 2018, Ampio disclosed that the U.S. Food and Drug Administration (“FDA”) notified the Company that the FDA does not consider the Company’s AP-003-C trial to be an adequate and well-controlled clinical trial, and that the Company’s AP-003-A study, alone, does not appear to provide sufficient evidence of effectiveness to support a biologics license application.
GlobeNewswirelast month
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (AMPE) of the October 24, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Ampio stock or options between December 14, 2017 and August 7, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMPE. There is no cost or obligation to you.
ACCESSWIRElast month
DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
GlobeNewswirelast month
Ampio October 24th Investor Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. - AMPE
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important October 24, 2018 lead plaintiff deadline in the shareholder class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE MKT: AMPE). The lawsuit seeks to recover damages on behalf of those who purchased the securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”). If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit Ampio Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.